Akari Therapeutics (AKTX) vs Estrella Immunopharma (ESLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Akari Therapeutics (AKTX) over the past year, losing 67.9% versus a loss of 79.5%. Over five years, ESLA leads with a -95.8% price change compared with -99.3% for AKTX. Akari Therapeutics is the larger company by market cap ($18.6 million vs $18.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | ESLA |
|---|---|---|
| Share price | $8.13 | $0.4175 |
| Market cap | $18.58M | $18.16M |
| 1-day change | -5.74% | -0.43% |
| YTD return | -25.39% | -73.24% |
| 1-year return | -79.46% | -67.88% |
| 5-year return | -99.35% | -95.77% |
| EPS (TTM) | $0.00 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.80 | $3.15 |
| 52-week low | $3.02 | $0.3611 |
| Distance from 52-week high | -81.00% | -86.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +2774.25% |
| Average volume | 60.35K | 38.27K |
| Shares outstanding | 2.29M | 43.50M |
| Employees | 5 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed AKTX by 11.6 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
AKTX vs ESLA FAQ
Which is bigger, Akari Therapeutics or Estrella Immunopharma?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $18.58M compared with $18.16M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, AKTX or ESLA?
ESLA returned -67.88% over the past 12 months, compared with -79.46% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Estrella Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.